ArticleInternational journal of cancer2026
Screening anticancer peptides performance in organotypic prostate tumor-stroma 3D models.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Prostate cancer (PCa) poses a significant concern in the realm of cancer, representing a continuous challenge for the scientific community to discover effective therapeutic approaches. Among emerging strategies, anticancer peptides have garnered attention for their potential to disrupt protein-protein interactions. Targeting protein phosphatase 1 (PP1) complexes through PP1-disrupting peptides holds promise for selectively impeding critical pathways in the development and progression of cancer. In this context, CAVPENET peptide was designed to specifically target and disrupt the complex formed between PP1 and caveolin-1, a contributor to the progression of PCa. Previous research has revealed that CAVPENET inhibits the growth of PCa cell 2D monolayers, primarily by modulating PP1 activity. In this study, we developed an increasing physiomimetic human 3D PCa/prostate cancer-associated fibroblast heterotypic spheroid model to evaluate the tumor-suppressive activity of CAVPENET peptide in a more relevant preclinical context. Our findings reveal the formation of morphologically well-defined tumor microtissues that increase their size and cellular density over time, characteristics of in vivo tumors. Upon incubation with CAVPENET, PCa spheroids exhibited decreased growth and viability. In contrast, CAVPENET treatment (20 μM) did not influence CAFs monotypic spheroids growth. In conclusion, our results underscore the relevance of employing 3D PCa-stroma heterotypic models for evaluating anticancer therapeutics and emphasize the therapeutic potential of CAVPENET peptide for PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.